Early evidence has built excitement for the investigational class of PCSK9 inhibitors, which have shown robust efficacy at cutting “bad” LDL cholesterol down to size. But positioning and pricing these biologicals in a market largely dominated by cheap and popular oral generics is sure to be a tough balancing act.
In recent months, new PCSK9 inhibitors have quickly captured the imagination of investors, clinicians and the media. Proprotein convertase subtilisin/kexin...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?